Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma (NCT04077515) | Clinical Trial Compass
CompletedPhase 4
Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma
China92 participantsStarted 2019-05-01
Plain-language summary
to evaluate the safety and efficacy of Low-dose sirolimus in Kaposiform Hemangioendothelioma in Chinese children by a prospective, randomized open trial.
Who can participate
Age range12 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Kaposiform Hemangioendotheliomas with or without Kasabach-Merritt Phenomenon.
* 0 - 12 years of age at the time of study entry.
* Male or female.
* Consent of parents (or the person having parental authority in families): Signed and dated written informed consent.
Exclusion Criteria:
* with hematological diseases.
* with other solid tumors.
* with hypertension, diabetes, adrenal insufficiency, neurological diseases, liver and kidney dysfunction, and cardiopulmonary insufficiency.
* with tuberculosis,cytomegalovirus and Epstein-Barr virus infection before the treatment.